Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Barinthus Biotherapeutics
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
August 08, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
BRNS
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 12, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
BRNS
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
ABUS
BRNS
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
May 22, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
BRNS
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
May 13, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
BRNS
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
May 01, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
BRNS
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
April 18, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
BRNS
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
March 20, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
BRNS
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
January 05, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
BRNS
New partnership aims to advance vaccine against MERS coronavirus
December 21, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
BRNS
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
November 09, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
ABUS
BRNS
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
November 09, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
BRNS
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
November 06, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Tickers
VACC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.